Connection
Todd Hankinson to Animals
This is a "connection" page, showing publications Todd Hankinson has written about Animals.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.074 |
|
|
|
-
Lakshmanachetty S, Riemondy K, Sanford B, Donson A, Chen V, Balakrishnan I, Prince EW, Hankinson T, Dahl N, Vibhakar R, Foreman N, Venkatraman S, Mitra SS. Differential phagocytosis induces diverse macrophage activation states in malignant gliomas. J Immunother Cancer. 2025 Sep 05; 13(9).
Score: 0.013
-
de Sousa GR, Calzadilla AJ, Grimaldo E, Donson AM, Sobral LM, Jones KM, Liu T, Amani V, Venkataraman S, Dahl NA, Levy JMM, Phang T, Vibhakar R, Hankinson T, Handler M, Valera ET, Foreman NK, Griesinger AM. Loss of LDOC1 by chromatin compaction in mesenchymal tumor cells is required for PFA1 ependymoma growth. Neuro Oncol. 2025 Jul 30; 27(6):1597-1610.
Score: 0.013
-
Apps JR, Gonzalez-Meljem JM, Guiho R, Pickles JC, Prince E, Schwalbe E, Joshi N, Stone TJ, Ogunbiyi O, Chalker J, Bassey A, Otto G, Davies R, Hughes D, Brandner S, Tan E, Lee V, Hayhurst C, Kline C, Castellano S, Hankinson T, Deutschbein T, Jacques TS, Martinez-Barbera JP. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression. Acta Neuropathol Commun. 2024 08 10; 12(1):127.
Score: 0.012
-
Griesinger AM, Calzadilla AJ, Grimaldo E, Donson AM, Amani V, Pierce AM, Steiner J, Kargar S, Serkova NJ, Bertrand KC, Wright KD, Vibhakar R, Hankinson T, Handler M, Lindsay HB, Foreman NK, Dorris K. Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma. Clin Cancer Res. 2024 Apr 15; 30(8):1544-1554.
Score: 0.011
-
Riemondy KA, Venkataraman S, Willard N, Nellan A, Sanford B, Griesinger AM, Amani V, Mitra S, Hankinson TC, Handler MH, Sill M, Ocasio J, Weir SJ, Malawsky DS, Gershon TR, Garancher A, Wechsler-Reya RJ, Hesselberth JR, Foreman NK, Donson AM, Vibhakar R. Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma. Neuro Oncol. 2022 02 01; 24(2):273-286.
Score: 0.010
-
Pierce AM, Witt DA, Donson AM, Gilani A, Sanford B, Sill M, Van Court B, Oweida A, Prince EW, Steiner J, Danis E, Dorris K, Hankinson T, Handler MH, Jones KL, Karam SD, Serkova NJ, Vibhakar R, Foreman NK, Griesinger AM. Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma. Neuro Oncol. 2019 12 17; 21(12):1540-1551.
Score: 0.008
-
Apps JR, Carreno G, Gonzalez-Meljem JM, Haston S, Guiho R, Cooper JE, Manshaei S, Jani N, Hölsken A, Pettorini B, Beynon RJ, Simpson DM, Fraser HC, Hong Y, Hallang S, Stone TJ, Virasami A, Donson AM, Jones D, Aquilina K, Spoudeas H, Joshi AR, Grundy R, Storer LCD, Korbonits M, Hilton DA, Tossell K, Thavaraj S, Ungless MA, Gil J, Buslei R, Hankinson T, Hargrave D, Goding C, Andoniadou CL, Brogan P, Jacques TS, Williams HJ, Martinez-Barbera JP. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. Acta Neuropathol. 2018 05; 135(5):757-777.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|